Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (382) 382
humans (334) 334
oncology (305) 305
colorectal cancer (265) 265
anti-egfr therapy (207) 207
cetuximab (200) 200
cancer (162) 162
chemotherapy (143) 143
mutation (127) 127
anti-egfr (121) 121
female (121) 121
colorectal neoplasms - drug therapy (118) 118
colorectal neoplasms - genetics (118) 118
panitumumab (116) 116
receptor, epidermal growth factor - antagonists & inhibitors (111) 111
metastasis (108) 108
care and treatment (101) 101
colorectal neoplasms - pathology (100) 100
growth-factor receptor (99) 99
kras (99) 99
1st-line treatment (97) 97
antineoplastic agents - therapeutic use (97) 97
male (96) 96
animals (83) 83
acquired-resistance (82) 82
middle aged (81) 81
tumors (81) 81
aged (79) 79
epidermal growth factor (79) 79
antibodies, monoclonal - therapeutic use (75) 75
monoclonal antibodies (72) 72
adult (61) 61
anti-egfr antibody (60) 60
genetic aspects (60) 60
prognosis (60) 60
analysis (58) 58
egfr (58) 58
cell line, tumor (56) 56
pharmacology & pharmacy (56) 56
therapy (56) 56
metastatic colorectal cancer (55) 55
braf (53) 53
research (53) 53
antineoplastic combined chemotherapy protocols - therapeutic use (52) 52
neoplasm metastasis (52) 52
cancer therapies (51) 51
health aspects (51) 51
cell lung-cancer (50) 50
open-label (50) 50
cetuximab plus irinotecan (49) 49
colorectal carcinoma (49) 49
metastatic colorectal-cancer (49) 49
ras proteins - genetics (47) 47
bevacizumab (46) 46
colorectal-cancer (46) 46
ras mutations (46) 46
receptor, epidermal growth factor - immunology (46) 46
targeted therapy (45) 45
medicine & public health (43) 43
receptor, epidermal growth factor - metabolism (43) 43
treatment outcome (43) 43
colon-cancer (42) 42
proto-oncogene proteins b-raf - genetics (42) 42
aged, 80 and over (41) 41
epidermal growth factor receptors (41) 41
hematology, oncology and palliative medicine (41) 41
molecular targeted therapy (41) 41
phase-iii trial (41) 41
resistance (41) 41
proto-oncogene proteins p21 - genetics (40) 40
digestive system diseases (39) 39
drug therapy (39) 39
expression (39) 39
metastases (39) 39
mice (39) 39
monoclonal-antibody (39) 39
patients (39) 39
cell biology (38) 38
survival (38) 38
antibodies, monoclonal, humanized (37) 37
fluorouracil (37) 37
kinases (37) 37
antineoplastic agents - pharmacology (36) 36
biomarkers (36) 36
lung-cancer (36) 36
antibodies, monoclonal - administration & dosage (35) 35
development and progression (35) 35
kras mutations (35) 35
mutations (35) 35
pathology (35) 35
proto-oncogene proteins - genetics (35) 35
antibodies (34) 34
biomarkers, tumor - genetics (34) 34
proto-oncogene proteins p21 (33) 33
medicine (32) 32
disease-free survival (31) 31
gene mutations (31) 31
studies (31) 31
antibodies, monoclonal - pharmacology (30) 30
neoplasms (30) 30
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (546) 546
French (28) 28
German (8) 8
Spanish (5) 5
Russian (3) 3
Czech (2) 2
Japanese (2) 2
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Blood‐based detection of RAS mutations to guide anti‐EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue‐based RAS testing
by Schmiegel, Wolff and Scott, Rodney J and Dooley, Susan and Lewis, Wendy and Meldrum, Cliff J and Pockney, Peter and Draganic, Brian and Smith, Steve and Hewitt, Chelsee and Philimore, Hazel and Lucas, Amanda and Shi, Elva and Namdarian, Kateh and Chan, Timmy and Acosta, Danilo and Ping‐Chang, Su and Tannapfel, Andrea and Reinacher‐Schick, Anke and Uhl, Waldemar and Teschendorf, Christian and Wolters, Heiner and Stern, Josef and Viebahn, Richard and Friess, Helmut and Janssen, Klaus‐Peter and Nitsche, Ulrich and Slotta‐Huspenina, Julia and Pohl, Michael and Vangala, Deepak and Baraniskin, Alexander and Dockhorn‐Dworniczak, Barbara and Hegewisch‐Becker, Susanne and Ronga, Philippe and Edelstein, Daniel L and Jones, Frederick S and Hahn, Stephan and Fox, Stephen B
Molecular Oncology, ISSN 1574-7891, 02/2017, Volume 11, Issue 2, pp. 208 - 219
An accurate blood‐based RAS mutation assay to determine eligibility of metastatic colorectal cancer ( mCRC ) patients for anti‐ EGFR therapy would benefit... 
ct | CRC | therapy | DNA | plasma | EGFR | RAS mutations | anti | anti-EGFR therapy | ctDNA | 1ST-LINE TREATMENT | PLUS CETUXIMAB TREATMENT | FOLLOW-UP | OPEN-LABEL | CELL LUNG-CANCER | PHASE-III TRIAL | GROWTH-FACTOR RECEPTOR | PREDICT RESPONSE | ONCOLOGY | KRAS | AMERICAN SOCIETY | ErbB Receptors - antagonists & inhibitors | DNA, Neoplasm - blood | Colorectal Neoplasms - blood | Colorectal Neoplasms - drug therapy | Colorectal Neoplasms - genetics | Humans | Female | Male | Aged | DNA, Neoplasm - genetics | Mutation | Genes, ras | Plasma | Epidermal growth factor receptors | Colorectal carcinoma | Colorectal cancer | Metastasis | Paraffin | Patients | Blood | Metastases | Ethics | Histopathology | Epidermal growth factor | Agreements | Clinical medicine | Deoxyribonucleic acid--DNA | DNA sequencing | Tumors | Index Medicus | anti‐EGFR therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
by van Cutsem, E and Cervantes, A and Adam, R and Sobrero, A and van Krieken, J. H and Aderka, D and Aranda Aguilar, E and Bardelli, A and Benson, A and Bodoky, G and Ciardiello, F and D'Hoore, A and Diaz-Rubio, E and Douillard, J.-Y and Ducreux, M and Falcone, A and Grothey, A and Gruenberger, T and Haustermans, K and Heinemann, V and Hoff, P and Köhne, C.-H and Labianca, R and Laurent-Puig, P and Ma, B and Maughan, T and Muro, K and Normanno, N and Österlund, P and Oyen, W. J. G and Papamichael, D and Pentheroudakis, G and Pfeiffer, P and Price, T. J and Punt, C and Ricke, J and Roth, A and Salazar, R and Scheithauer, W and Schmoll, H. J and Tabernero, J and Taïeb, J and Tejpar, S and Wasan, H and Yoshino, T and Zaanan, A and Arnold, D
Annals of oncology, ISSN 0923-7534, 2016, Volume 27, Issue 8, pp. 1386 - 1422
The clinical outcome for patients with metastatic CRC (mCRC) has improved greatly over the last 20 years. These ESMO consensus guidelines have been developed... 
ESMO | Clinical practice guidelines | Consensus | Colorectal cancer | UNRESECTABLE LIVER METASTASES | colorectal cancer | ANTI-EGFR THERAPY | WILD-TYPE KRAS | PERITONEAL SURFACE MALIGNANCIES | consensus | clinical practice guidelines | K-RAS MUTATIONS | CIRCULATING TUMOR DNA | ONCOLOGY | RANDOMIZED PHASE-III | STEREOTACTIC BODY RADIOTHERAPY | CETUXIMAB PLUS IRINOTECAN | OXALIPLATIN-BASED CHEMOTHERAPY | Guidelines as Topic | Neoplasm Metastasis | Prognosis | Colorectal Neoplasms - drug therapy | Colorectal Neoplasms - genetics | Humans | Biomarkers, Tumor - genetics | Colorectal Neoplasms - pathology | Molecular Targeted Therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Establishment of Patient-Derived Non–Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers
by Iduna Fichtner and Jana Rolff and Richie Soong and Jens Hoffmann and Stefanie Hammer and Anette Sommer and Michael Becker and Johannes Merk
Clinical Cancer Research, ISSN 1078-0432, 10/2008, Volume 14, Issue 20, pp. 6456 - 6468
Purpose: It was the aim of our study to establish an extensive panel of non-small cell lung cancer (NSCLC) xenograft models useful for the testing of novel... 
xenograft | NSCLC | erlotinib | mutational analysis | anti-EGFR therapy | cetuximab | biomarker | TARGETED THERAPY | KRAS MUTATIONS | GROWTH-FACTOR RECEPTOR | NUDE-MICE | TUMOR XENOGRAFTS | GEFITINIB | ONCOLOGY | GENE-EXPRESSION | TYROSINE KINASE INHIBITOR | EGFR MUTATIONS | ANTITUMOR-ACTIVITY | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Adenocarcinoma - pathology | Oligonucleotide Array Sequence Analysis | Carcinoma, Large Cell - pathology | Carcinoma, Squamous Cell - pathology | Humans | Lung Neoplasms - metabolism | Middle Aged | Drug Resistance, Neoplasm | Immunoblotting | Male | Gene Expression Profiling | Adenocarcinoma - metabolism | Biomarkers, Tumor - metabolism | Cetuximab | Disease Models, Animal | Genes, ras - genetics | Antibodies, Monoclonal - pharmacology | Carcinoma, Non-Small-Cell Lung - metabolism | Etoposide - pharmacology | Mutation - genetics | Adenocarcinoma - drug therapy | Small Cell Lung Carcinoma - pathology | Carcinoma, Squamous Cell - drug therapy | Mice, Nude | Mice, Inbred NOD | Biomarkers, Tumor - genetics | Mice | Carboplatin - pharmacology | Quinazolines - pharmacology | Deoxycytidine - analogs & derivatives | Erlotinib Hydrochloride | Paclitaxel - pharmacology | Prognosis | Carcinoma, Squamous Cell - metabolism | Deoxycytidine - pharmacology | Lung Neoplasms - pathology | Small Cell Lung Carcinoma - drug therapy | Tumor Suppressor Protein p53 - genetics | Small Cell Lung Carcinoma - metabolism | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Vinblastine - analogs & derivatives | Polymerase Chain Reaction | Adult | Female | Antineoplastic Agents - pharmacology | Carcinoma, Non-Small-Cell Lung - pathology | Carcinoma, Large Cell - metabolism | Radiation-Sensitizing Agents - pharmacology | Tumor Suppressor Protein p53 - metabolism | Mice, SCID | Xenograft Model Antitumor Assays | Animals | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Protein Kinase Inhibitors - pharmacology | Vinblastine - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Antineoplastic Agents, Phytogenic - pharmacology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan plus /- targeted therapy
by Nielsen, DL and Palshof, JA and Larsen, FO and Jensen, BV and Pfeiffer, P
CANCER TREATMENT REVIEWS, ISSN 0305-7372, 07/2014, Volume 40, Issue 6, pp. 701 - 715
Oxaliplatin, irinotecan and 5-fluorouracil in combination with or without targeted therapies are well-documented treatment options for first- and second-line... 
3RD-LINE CHEMOTHERAPY | Targeted therapy | MITOMYCIN-C | Colorectal cancer | ANTI-EGFR THERAPY | Salvage therapy | Refractory | LIVER METASTASES | K-RAS MUTATIONS | Chemotherapy | PHASE-II TRIAL | HEPATIC ARTERIAL INFUSION | ONCOLOGY | EVERY 2 WEEKS | COMBINATION CHEMOTHERAPY | GROWTH-FACTOR
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer
by Bardelli, Alberto and Corso, Simona and Bertotti, Andrea and Hobor, Sebastijan and Valtorta, Emanuele and Siravegna, Giulia and Sartore-Bianchi, Andrea and Scala, Elisa and Cassingena, Andrea and Zecchin, Davide and Apicella, Maria and Migliardi, Giorgia and Galimi, Francesco and Lauricella, Calogero and Zanon, Carlo and Perera, Timothy and Veronese, Silvio and Corti, Giorgio and Amatu, Alessio and Gambacorta, Marcello and Diaz Jr, Luis A and Sausen, Mark and Velculescu, Victor E and Comoglio, Paolo and Trusolino, Livio and Di Nicolantonio, Federica and Giordano, Silvia and Siena, Salvatore
Cancer Discovery, ISSN 2159-8274, 2013, Volume 3, Issue 6, pp. 658 - 673
EGF receptor (EGFR)-targeted monoclonal antibodies are effective in a subset of metastatic colorectal cancers. Inevitably, all patients develop resistance,... 
LUNG-CANCER | CETUXIMAB | GEFITINIB | ONCOLOGY | TYROSINE KINASE | GROWTH | ACQUIRED-RESISTANCE | PHASE-II | MONOCLONAL-ANTIBODY | AUTOCRINE ACTIVATION | GENE COPY NUMBER | Proto-Oncogene Proteins c-met - metabolism | Antibodies, Monoclonal, Humanized - adverse effects | Receptor, Epidermal Growth Factor - genetics | Antibodies, Monoclonal - pharmacology | Colorectal Neoplasms - genetics | Humans | Antibodies, Monoclonal - adverse effects | Drug Resistance, Neoplasm | Random Allocation | Mice, SCID | Proto-Oncogene Proteins c-met - genetics | Xenograft Model Antitumor Assays | Animals | Antineoplastic Agents - adverse effects | Antibodies, Monoclonal, Humanized - pharmacology | Colorectal Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice, Inbred NOD | Antineoplastic Agents - pharmacology | Mice | Proto-Oncogene Proteins c-met - pharmacology | Cetuximab | Colorectal Neoplasms - pathology | Genes, ras | Index Medicus | Acquired resistance | Colorectal cancer | cetuximab | Met tyrosine kinase receptor | MET | Anti-EGFR therapy | EGFR
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer
by Grasselli, J and Elez, E and Caratù, G and Matito, J and Santos, C and Macarulla, T and Vidal, J and Garcia, M and Viéitez, J.M and Paéz, D and Falcó, E and Lopez Lopez, C and Aranda, E and Jones, F and Sikri, V and Nuciforo, P and Fasani, R and Tabernero, J and Montagut, C and Azuara, D and Dienstmann, R and Salazar, R and Vivancos, A
Annals of Oncology, ISSN 0923-7534, 06/2017, Volume 28, Issue 6, pp. 1294 - 1301
Background: Circulating tumor DNA (ctDNA) is a potential source for tumor genome analysis. We explored the concordance between the mutational status of RAS in... 
Anti-EGFR therapy | Circulating tumor DNA | Metastatic colorectal cancer | RAS analysis | KRAS MUTATIONS | EVOLUTION | ONCOLOGY | ACQUIRED-RESISTANCE | anti-EGFR therapy | metastatic colorectal cancer | BLOCKADE | circulating tumor DNA | Neoplasm Metastasis | Colorectal Neoplasms - blood | Colorectal Neoplasms - drug therapy | Colorectal Neoplasms - genetics | Humans | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mutation | Colorectal Neoplasms - pathology | Genes, ras | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Significance of FGF9 gene in resistance to anti‐EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti‐EGFR therapies
by Mizukami, Takuro and Togashi, Yosuke and Naruki, Saeko and Banno, Eri and Terashima, Masato and de Velasco, Marco A and Sakai, Kazuko and Yoneshige, Azusa and Hayashi, Hidetoshi and Fujita, Yoshihiko and Tomida, Shuta and Nakajima, Takako Eguchi and Fujino, Takashi and Boku, Narikazu and Ito, Akihiko and Nakagawa, Kazuhiko and Nishio, Kazuto
Molecular Carcinogenesis, ISSN 0899-1987, 01/2017, Volume 56, Issue 1, pp. 106 - 117
Although fibroblast growth factor (FGF) signals are strongly associated with malignancy, limited information is available regarding the role of the FGF9 signal... 
KRAS | colorectal cancer | drug resistance | FGF9 | anti‐EGFR therapy | anti-EGFR therapy | GROWTH-FACTOR 9 | 1ST-LINE TREATMENT | BIOCHEMISTRY & MOLECULAR BIOLOGY | FLUOROURACIL | TUMORS | CETUXIMAB | OVEREXPRESSION | AMPLIFICATION | ONCOLOGY | MUTATIONS | EXPRESSION | CARCINOMA | Up-Regulation | Rectum - pathology | Colorectal Neoplasms - genetics | Humans | Middle Aged | Colon - drug effects | Male | Antineoplastic Agents - therapeutic use | Fibroblast Growth Factor 9 - genetics | Rectum - drug effects | Colorectal Neoplasms - drug therapy | Female | Antineoplastic Agents - pharmacology | Colon - pathology | Rectum - metabolism | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | Phenylurea Compounds - therapeutic use | Pyrimidines - pharmacology | Colon - metabolism | Animals | Mice, Nude | Pyrimidines - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Mice, Inbred BALB C | Phenylurea Compounds - pharmacology | Colorectal Neoplasms - pathology | Drug Resistance, Neoplasm - drug effects | Immunohistochemistry | Medical colleges | Care and treatment | RNA | Analysis | Genes | Colorectal cancer | Genetic research | Fibroblast growth factors | Genetic aspects | Health aspects | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
by Normanno, Nicola and Rachiglio, A.M and Lambiase, M and Martinelli, E and Fenizia, F and Esposito, C and Roma, C and Troiani, T and Rizzi, D and Tatangelo, F and Botti, G and Maiello, E and Colucci, G and Ciardiello, F and Giuliani, F and Simone, G and Febbraro, A and Tommaselli, E and Cinieri, S and Criscuolo, M and Rinaldi, A and Bordonaro, R and Manusia, M and Romito, S and Bufo, P and Cartenì, G and Biglietto, M and Nappi, O and Montesarchio, E and Micheli, P and Nasti, G and Chicchinelli, N and Iannaccone, A and Russo, A and Cabibi, D and Barone, C and Rindi, G and Tonini, G and Onetti Muda, A and Perrone, G and Latiano, T and Graziano, P and Pisconti, S and Sebastio, A and CAPRI GOIM investigators and CAPRI-GOIM investigators
Annals of Oncology, ISSN 0923-7534, 2015, Volume 26, Issue 8, pp. 1710 - 1714
Background: Evidence suggests that metastatic colorectal carcinoma (mCRC) has a high level of intratumor heterogeneity. We carried out a quantitative... 
Tumor heterogeneity | Mutations | Next-generation sequencing | Cetuximab | Colorectal cancer | colorectal cancer | next-generation sequencing | cetuximab | ANTI-EGFR THERAPY | COLON | CONCORDANCE | TARGETED THERAPIES | mutations | EVOLUTION | ONCOLOGY | FOLFIRI PLUS CETUXIMAB | RESISTANCE | GENETIC-HETEROGENEITY | tumor heterogeneity | Proto-Oncogene Proteins p21(ras) - genetics | Colorectal Neoplasms - genetics | Humans | Fluorouracil - therapeutic use | Colorectal Neoplasms - drug therapy | Leucovorin - therapeutic use | Camptothecin - analogs & derivatives | Carcinoma - secondary | Carcinoma - drug therapy | Camptothecin - therapeutic use | Membrane Proteins - genetics | Gene Frequency | Treatment Outcome | Phosphatidylinositol 3-Kinases - genetics | Drug Resistance, Neoplasm - genetics | Class I Phosphatidylinositol 3-Kinases | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Carcinoma - genetics | Cetuximab - administration & dosage | High-Throughput Nucleotide Sequencing | Mutation | Colorectal Neoplasms - pathology | Organoplatinum Compounds - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. miRNAs as Modulators of EGFR Therapy in Colorectal Cancer
by Pereira, Diane M and Rodrigues, Cecília M P and Rodrigues, Cecília M. P
Advances in experimental medicine and biology, ISSN 0065-2598, 2018, Volume 1110, pp. 133 - 147
Drug resistance is a serious impediment to the treatment of cancer. The use of anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapies in... 
miRNA | Therapy resistance | Anti-EGFR therapy | Epidermal growth factor receptor | Prognostic marker | CIRCULATING MICRORNAS | 1ST-LINE TREATMENT | TARGETING KRAS | DOWN-REGULATION | WILD-TYPE KRAS | DEPENDENT CELLULAR CYTOTOXICITY | PHASE-III TRIAL | MESSENGER-RNAS | ONCOLOGY | RAS MUTATIONS | MICRORNA EXPRESSION
Journal Article
Details down arrow
10. Full Text Acquired resistance to EGFR-targeted therapies incolorectal cancer
by Van Emburgh, Beth O and Sartore-Bianchi, Andrea and Di Nicolantonio, Federica and Siena, Salvatore and Bardelli, Alberto
Molecular Oncology, ISSN 1574-7891, 09/2014, Volume 8, Issue 6, pp. 1084 - 1094
Cetuximab and panitumumab are anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies used as therapies for metastatic colorectal cancer... 
Acquired resistance | RAS | Panitumumab | Colorectal cancer | Cetuximab | Anti-EGFR therapy | MET
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer
by Tougeron, D and Lecomte, T and Pagès, J.C and Villalva, C and Collin, C and Ferru, A and Tourani, J.M and Silvain, C and Levillain, P and Karayan-tapon, L
Annals of Oncology, ISSN 0923-7534, 05/2013, Volume 24, Issue 5, pp. 1267 - 1273
Background: Only patients with wild-type (WT) KRAS tumors benefit from anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (Mabs) in metastatic... 
KRAS mutation | Anti-EGFR monoclonal antibodies | Colorectal cancer | Pyrosequencing | 1ST-LINE TREATMENT | LEUCOVORIN | colorectal cancer | pyrosequencing | BRAF | FLUOROURACIL | anti-EGFR monoclonal antibodies | CHEMOTHERAPY | CETUXIMAB-PLUS-IRINOTECAN | PHASE-III TRIAL | GROWTH-FACTOR RECEPTOR | ONCOLOGY | RAS MUTATIONS | RESISTANCE | Receptor, Epidermal Growth Factor - immunology | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Proto-Oncogene Proteins - genetics | Antineoplastic Agents - therapeutic use | Sequence Analysis, DNA | Colorectal Neoplasms - immunology | Neoplasm Metastasis - drug therapy | Base Sequence | Colorectal Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Female | Aged | Biomarkers, Tumor - genetics | Retrospective Studies | Mutation | Colorectal Neoplasms - pathology | Antibodies, Monoclonal - immunology | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance
by Zhai, ZH and Yu, XH and Yang, B and Zhang, YJ and Zhang, L and Li, XL and Sun, HZ
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, ISSN 1084-9521, 04/2017, Volume 64, pp. 107 - 115
Precision medicine is becoming considerably critical in colorectal cancer therapy. Particularly for targeted therapies, the response to anti-EGFR therapy... 
EGFR MONOCLONAL-ANTIBODIES | PREDICTIVE BIOMARKER | INHIBITOR CETUXIMAB | Colorectal cancer | ACQUIRED-RESISTANCE | DEVELOPMENTAL BIOLOGY | Drug resistance | TUMOR HETEROGENEITY | CELL BIOLOGY | Heterogeneity | GROWTH-FACTOR RECEPTOR | Anti-EGFR therapies | CETUXIMAB PLUS IRINOTECAN | GENE COPY NUMBER | KRAS P.G13D MUTATION | EPIGENETIC ALTERATIONS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Cancer Stem Cell‐Based Models of Colorectal Cancer Reveal Molecular Determinants of Therapy Resistance
by De Angelis, Maria Laura and Zeuner, Ann and Policicchio, Eleonora and Russo, Giorgio and Bruselles, Alessandro and Signore, Michele and Vitale, Sara and De Luca, Gabriele and Pilozzi, Emanuela and Boe, Alessandra and Stassi, Giorgio and Ricci-Vitiani, Lucia and Amoreo, Carla Azzurra and Pagliuca, Alfredo and Francescangeli, Federica and Tartaglia, Marco and De Maria, Ruggero and Baiocchi, Marta
STEM CELLS Translational Medicine, ISSN 2157-6564, 04/2016, Volume 5, Issue 4, pp. 511 - 523
Colorectal cancer stem cell (CSC)‐enriched cultures were obtained efficiently from primary tumor specimens by optimizing a CSC‐isolation protocol. Based on in... 
Cancer stem cells | Cetuximab | Proteomic arrays | Anti-EGFR therapy | Colorectal cancer | INITIATING CELLS | HUMAN COLON | EGFR-TARGETED THERAPIES | CULTURE | TUMORS | DISCOVERY | GENOME | CELL & TISSUE ENGINEERING | EXPANSION | FRAMEWORK | DNA-SEQUENCING DATA | Neoplastic Stem Cells - drug effects | Colorectal Neoplasms - genetics | Humans | Cells, Cultured | Mice, Transgenic | Gene Expression Profiling | Signal Transduction - genetics | Mice, SCID | Drug Resistance, Neoplasm - genetics | Animals | Neoplastic Stem Cells - metabolism | Microarray Analysis | Models, Biological | Proteomics | Neoplastic Stem Cells - pathology | Female | Mice, Inbred NOD | Protein Kinase Inhibitors - pharmacology | Colorectal Neoplasms - pathology | Cell culture | Flow cytometry | Epidermal growth factor receptors | Colorectal carcinoma | Experiments | Cancer therapies | Drug testing | Spheroids | Chemotherapy | Epidermal growth factor | Molecular modelling | Medical prognosis | Genetic analysis | Stem cells | Tumors | Cancer | Index Medicus | Cancer Stem Cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text A short interval between bevacizumab and anti-epithelial growth factor receptor therapy interferes with efficacy of subsequent anti-EGFR therapy for refractory colorectal cancer
by Taniguchi, Hiroya and Komori, Azusa and Narita, Yukiya and Kadowaki, Shigenori and Ura, Takashi and Andoh, Masashi and Yatabe, Yasushi and Komori, Koji and Kimura, Kenichi and Kinoshita, Takashi and Muro, Kei
Japanese Journal of Clinical Oncology, ISSN 0368-2811, 03/2016, Volume 46, Issue 3, pp. 228 - 233
Both bevacizumab and anti-epithelial growth factor receptor (EGFR) agents (e.g. cetuximab and panitumumab) are sequentially used for metastatic colorectal... 
Anti-EGFR antibody | Colorectal cancer | Bevacizumab | Interval | ANTIBODIES | 1ST-LINE TREATMENT | colorectal cancer | PHASE-III | WILD-TYPE KRAS | OPEN-LABEL | TUMOR ANGIOGENESIS | CHEMOTHERAPY | K-RAS MUTATIONS | CETUXIMAB | ONCOLOGY | bevacizumab | anti-EGFR antibody | interval | PANITUMUMAB PLUS | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Fluorouracil - administration & dosage | Time Factors | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Camptothecin - administration & dosage | Female | Retrospective Studies | Camptothecin - analogs & derivatives | Receptor, Epidermal Growth Factor - immunology | Bevacizumab - administration & dosage | Drug Administration Schedule | Treatment Outcome | Vascular Endothelial Growth Factor A - immunology | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text The influence of KRAS and BRAF mutations on the efficacy of cetuximab‐based first‐line therapy of metastatic colorectal cancer: An analysis of the AIO KRK‐0104‐trial
by Modest, D.P and Jung, A and Moosmann, N and Laubender, R.P and Giessen, C and Schulz, C and Haas, M and Neumann, J and Boeck, S and Kirchner, T and Heinemann, V and Stintzing, S
International Journal of Cancer, ISSN 0020-7136, 08/2012, Volume 131, Issue 4, pp. 980 - 986
Our study investigated the impact of specific KRAS mutations and BRAF mutation on progression‐free survival (PFS) and overall survival (OS) in patients with... 
codon 13 | codon 12 | KRAS | BRAF | mCRC | anti‐EGFR | anti-EGFR | SURVIVAL | LEUCOVORIN | STAGE | OXALIPLATIN | FLUOROURACIL | CHEMOTHERAPY | PANITUMUMAB | ONCOLOGY | RAS MUTATIONS | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Antineoplastic Agents - therapeutic use | Antibodies, Monoclonal, Humanized | Neoplasm Metastasis | Proto-Oncogene Proteins B-raf - genetics | Colorectal Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adult | Female | Aged | Mutation | Cetuximab | Colorectal Neoplasms - pathology | Genes, ras | Chemotherapy | Metastasis | Colorectal cancer | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights